Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Messoud Ashina

Showing results (311-320 of 432) with videos related to

Pageof 44
Sort By:
Pain|July 12, 2021
Opening of BKCa channels causes migraine attacks: a new downstream target for the treatment of migraineMohammad Al-Mahdi Al-Karagholi, Hashmat Ghanizada, Cherie Amalie Waldorff Nielsen, et al.
The Journal of Headache and Pain|September 7, 2023
Calcitonin gene-related peptide causes migraine auraHaidar M Al-Khazali, Håkan Ashina, Astrid Wiggers, et al.
Cephalalgia : an International Journal of Headache|November 19, 2025
Rimegepant for acute treatment of migraine in triptan-unsuitable adults: A randomized, double-blind, placebo-controlled phase 4 trialMessoud Ashina, Peter McAllister, Charly Gaul, et al.
Cephalalgia : an International Journal of Headache|March 20, 2016
Part II: Biochemical changes after pituitary adenylate cyclase-activating polypeptide-38 infusion in migraine patientsSong Guo, Anne Luise Haulund Vollesen, Young Bae Lee Hansen, et al.
Neurology|August 25, 2017
Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label studyMessoud Ashina, David Dodick, Peter J Goadsby, et al.
The Journal of Headache and Pain|February 26, 2020
Investigation of sumatriptan and ketorolac trometamol in the human experimental model of headacheHashmat Ghanizada, Mohammad Al-Mahdi Al-Karagholi, Nanna Arngrim, et al.
Cephalalgia : an International Journal of Headache|August 28, 2023
Patient-reported migraine-specific quality of life, activity impairment and headache impact with once-daily atogepant for preventive treatment of migraine in a randomized, 52-week trialRichard B Lipton, Rashmi B Halker Singh, Laszlo Mechtler, et al.
Headache|November 13, 2010
Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trialKathryn M Connor, Sheena K Aurora, Tom Loeys, et al.
Journal of Medical Economics|March 7, 2025
Lost earnings among triptan non-responders in the general population of Denmark: a measure of disproportionate migraine-attributed burden and of unrecognised and unmet treatment needMessoud Ashina, Timothy J Steiner, Jakob Møller Hansen, et al.
Cephalalgia : an International Journal of Headache|September 26, 2024
Cost of illness and labour market disaffiliation among patients with migraine discontinuing triptan treatment: A Danish nationwide register study from 1995 to 2021Messoud Ashina, Timothy J Steiner, Jakob Møller Hansen, et al.
Pageof 44

Showing results (311-320 of 432) with videos related to

Sort By:
Pageof 44
Pain|July 12, 2021
Opening of BKCa channels causes migraine attacks: a new downstream target for the treatment of migraineMohammad Al-Mahdi Al-Karagholi, Hashmat Ghanizada, Cherie Amalie Waldorff Nielsen, et al.
The Journal of Headache and Pain|September 7, 2023
Calcitonin gene-related peptide causes migraine auraHaidar M Al-Khazali, Håkan Ashina, Astrid Wiggers, et al.
Cephalalgia : an International Journal of Headache|November 19, 2025
Rimegepant for acute treatment of migraine in triptan-unsuitable adults: A randomized, double-blind, placebo-controlled phase 4 trialMessoud Ashina, Peter McAllister, Charly Gaul, et al.
Cephalalgia : an International Journal of Headache|March 20, 2016
Part II: Biochemical changes after pituitary adenylate cyclase-activating polypeptide-38 infusion in migraine patientsSong Guo, Anne Luise Haulund Vollesen, Young Bae Lee Hansen, et al.
Neurology|August 25, 2017
Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label studyMessoud Ashina, David Dodick, Peter J Goadsby, et al.
The Journal of Headache and Pain|February 26, 2020
Investigation of sumatriptan and ketorolac trometamol in the human experimental model of headacheHashmat Ghanizada, Mohammad Al-Mahdi Al-Karagholi, Nanna Arngrim, et al.
Cephalalgia : an International Journal of Headache|August 28, 2023
Patient-reported migraine-specific quality of life, activity impairment and headache impact with once-daily atogepant for preventive treatment of migraine in a randomized, 52-week trialRichard B Lipton, Rashmi B Halker Singh, Laszlo Mechtler, et al.
Headache|November 13, 2010
Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trialKathryn M Connor, Sheena K Aurora, Tom Loeys, et al.
Journal of Medical Economics|March 7, 2025
Lost earnings among triptan non-responders in the general population of Denmark: a measure of disproportionate migraine-attributed burden and of unrecognised and unmet treatment needMessoud Ashina, Timothy J Steiner, Jakob Møller Hansen, et al.
Cephalalgia : an International Journal of Headache|September 26, 2024
Cost of illness and labour market disaffiliation among patients with migraine discontinuing triptan treatment: A Danish nationwide register study from 1995 to 2021Messoud Ashina, Timothy J Steiner, Jakob Møller Hansen, et al.
Pageof 44